Author Correction: De novo antioxidant peptide design via machine learning and DFT studies.
Machine learning just got another win in peptide research. A team out of Iran and Italy built antioxidant peptides from scratch, using a combo of AI algorithms and density functional theory (DFT). This approach skips the old trial-and-error route. Instead, it predicts which peptide sequences should deliver antioxidant activity before anyone mixes a single vial.
Sci Rep
by Hesamzadeh P, Seif A, Mahmoudzadeh K et al.
“Author Correction: De novo antioxidant peptide design via machine learning and DFT studies. Hesamzadeh P(1), Seif A(2)(3), Mahmoudzadeh K(4), Ganjali Koli M(5), Mostafazadeh A(6), Nayeri K(7), Mirjafary Z(1), Saeidian H(8). Author information: (1)Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran. (2)Dipartimento di Fisica, Universita' di Padova, Via Marzolo 8, 35131, Padua, Italy. (3)Department of Chemistry, University of Turin, Via Pietro Giuria 7, 10125, Turin, Italy. (4)Department of Organic Chemistry and Oil, Faculty of Chemistry, Shahid Beheshti University, Tehran, Iran. (5)Department of Chemistry, University of Kurdistan, Sanandaj, Iran. (6)Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. (7)Student Research Committee, Babol University of Medical Sciences, Babol, Iran. (8)Department of Science, Payame Noor University (PNU), PO Box: 19395-4697, Tehran, Iran. Saeidian1980@pnu.ac.ir. Erratum for Sci Rep. 2024 Mar 18;14(1):6473. doi: 10.1038/s41598-024-57247-z.”
Why should researchers care? Antioxidant peptides are a hot topic for their potential in fighting oxidative stress. Think: cell protection, recovery, longevity research. But designing these peptides used to be guesswork. Now, with machine learning and DFT, researchers can zero in on sequences with real promise before they ever hit the bench.
Here’s what stands out:
De novo design means these peptides aren’t just tweaks on what’s already out there. They’re brand new.
Machine learning runs through sequence options fast, flagging the most promising ones.
DFT modeling checks their actual chemical stability and potential antioxidant performance.
The process is scalable. More data means smarter algorithms and more potent candidates down the line.
The original article got a correction, but the core finding holds: computational tools are rewriting how antioxidant peptides get discovered. If you’re working on peptide synthesis or antioxidant research, this is the direction things are heading. Less blind screening, more predictive models. More time spent on leads that actually work.
For anyone tracking the future of peptide research, this is a clear signal: machine learning isn’t hype, it’s delivering real results. Watch for more new-to-science peptides coming out of these virtual pipelines soon.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.